Navigation Links
Spherix Reports First Quarter 2009 Earnings

BETHESDA, Md., May 14 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported results for the first quarter ended March 31, 2009.

Recent Company Highlights

  • Biospherics
    • Created a wholly owned subsidiary, Biospherics Incorporated, for the Company's biotech segment.
    • Naturlose(R) Phase 3 clinical trial investigating efficacy as a treatment for Type 2 diabetes ongoing:
      • Interim data results expected in third quarter of 2009
      • Completion of the related Phase 2 Dose Range trial expected in early 2010
      • Trial completion expected in mid- to late-2010
    • Trade shows/investor conferences:
      • Ohio Valley Affiliates for Life Science, Dayton, OH, April 2-3
      • BIO International Convention, Atlanta, GA, May 18-21
      • Rodman & Renshaw 11th Annual Health Conference, New York, NY, Sept. 9-11

  • Spherix Consulting
    • Created a wholly owned subsidiary, Spherix Consulting, Inc., for the Company's health sciences segment.
    • Strong growth from health sciences consulting services.
    • Trade shows Spherix Consulting has and will be attending:
      • Society of Toxicology 48th Annual Meeting, Baltimore, MD, March 15-19
      • Institute of Food Technologists Annual Meeting and Food Expo, Anaheim, CA, June 6-9
      • American College of Toxicology, 30th Annual Meeting, Palm Springs, CA, Nov. 1-4
      • Supply Side West, Las Vegas, NV, Nov. 11-13

"We are pleased with the excellent growth of our health sciences consulting business," commented Dr. Claire L. Kruger, CEO of Spherix. "This is an exciting time at Spherix as we await the interim data in the fall from our ongoing Phase 3 clinical trial investigating the efficacy of Naturlose as a novel treatment for Type 2 diabetes."

Financial Results for the Quarter Ended March 31, 2009

Revenue and direct contract costs grew to $360,670 from $142,908 from the previous year's quarter. The Company's revenue improvement reflects the growth of its health sciences consulting services ("Spherix Consulting").

Research and development expenses were $1.6 million in the quarter, up from $1.0 million in the previous year's quarter. The increase in R&D expenses is related to the expansion of the Phase 3 trial to India. The Company's R&D expenses for both years consisted of costs for both the Phase 3 clinical trial and a related Phase 2 Dose Range trial.

Selling, general and administrative expenses for the quarter were $759,270, down from $1.1 million in the first quarter of 2008. The drop was largely the result of the relocation of the Company's Headquarters to a smaller facility in April 2008, and lower overhead costs.

The Company's losses from continuing operations were $2.0 million for the first quarters ended 2009 and 2008.

The net loss for the quarter ended March 31, 2009 was $2.0 million or $0.14 per share, compared with a net loss of $1.9 million or $0.13 per share for the same period in 2008.

Update on Naturlose(R) Phase 3 Clinical Trial

Patient retention in the India trial has been consistent with that of the U.S. thus far. The Company expects that the Phase 2 Dose Range trial will likely be completed in early 2010 and the Phase 3 trial will likely be completed in mid- to late-2010, based on the current enrollment and retention numbers. The Company expects to obtain interim analysis results from the Phase 3 trial during the third quarter of 2009, which may allow the Company some preliminary insight as to the efficacy of Naturlose as a treatment for Type 2 diabetes.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research. The company now leverages its scientific and technical expertise and experience through its two subsidiaries -- Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is currently running a Phase 3 clinical trial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop Naturlose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

                                 - Tables Follow -

                                Spherix Incorporated
                       Consolidated Statements of Operations
                   For the Quarters Ended March 31, 2009 and 2008

                                                Three Months Ended March 31,
                                                   2009              2008
                                                   ----              ----

    Revenue                                       $360,670          $142,908
                                                  --------          --------
    Operating expense
             Direct costs                          130,542            61,594
             Research and development expense    1,561,389         1,031,208
             Selling, general and administrative
              expense                              759,270         1,100,915
                                                   -------         ---------
             Total operating expense             2,451,201         2,193,717
                                                 ---------         ---------

    Loss from operations                        (2,090,531)       (2,050,809)
             Interest income                        24,447           136,575
                                                    ------           -------
    Loss before taxes                           (2,066,084)       (1,914,234)
             Income tax expense                          -                 -
                                                       ---               ---
    Net loss                                   $(2,066,084)      $(1,914,234)
                                              ============      ============

    Net loss per share, basic                       $(0.14)           $(0.13)
    Net loss per share, diluted                     $(0.14)           $(0.13)

    Weighted average shares outstanding, basic  14,357,162        14,318,702
                                                ==========        ==========
    Weighted average shares outstanding,
     diluted                                    14,357,162        14,318,702
                                                ----------        ----------

                               Spherix Incorporated
                            Consolidated Balance Sheets
                As of March 31, 2009 (unaudited), and December 31, 2008

                                              March 31, 2009  December 31,
    ASSETS                                      (Unaudited)       2008
                                              --------------  ------------
    Current assets
         Cash and cash equivalents              $7,778,180    $9,404,843
         Short-term investments                  2,029,352     1,894,434
         Trade accounts receivable                 189,617       281,342
         Other receivables                          13,681        37,223
         Prepaid expenses and other assets         177,352       282,971
                                                   -------       -------
              Total current assets              10,188,182    11,900,813

         Property and equipment, net               288,975       310,365
         Patents, net of accumulated
          amortization of $40,105 and $38,588       12,915        14,433
         Deposit                                    35,625        35,625
                                                    ------        ------
                   Total assets                $10,525,697   $12,261,236
                                               -----------   -----------

    Current liabilities
         Accounts payable and accrued expenses  $1,180,489      $710,881
         Accrued salaries and benefits             152,289       304,756
         Deferred revenue                           76,423        39,347
                                                    ------        ------
                   Total current liabilities     1,409,201     1,054,984

         Deferred compensation                     635,000       660,000
         Deferred rent                             130,124       136,736
                                                   -------       -------
                   Total liabilities             2,174,325     1,851,720
                                                 ---------     ---------

    Commitments and contingencies                        -             -

    Stockholders' equity
         Preferred stock, $0.01 par value,
          2,000,000 shares authorized;
          none issued and outstanding                    -             -
         Common stock, $0.005 par value,
          50,000,000 shares authorized;
          14,437,600 issued, and 14,357,162
          shares outstanding at March 31, 2009
          and December 31, 2008                     72,188        72,188
         Paid-in capital in excess of par value 27,610,426    27,602,486
         Treasury stock, 80,438 shares,
          at cost at March 31, 2009 and
          December 31, 2008                       (464,786)     (464,786)
         Accumulated deficit                   (18,866,456)  (16,800,372)
                                                ----------    ----------
              Total stockholders' equity         8,351,372    10,409,516
                                                 ---------    ----------
              Total liabilities and
               stockholders' equity            $10,525,697   $12,261,236
                                               -----------   -----------

SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Spherix Reports Second Quarter Earnings
2. Growth Achieved in Spherixs Health Sciences Consulting Business
3. Spherix D-tagatose to be Supplied by Inalco SpA
4. Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.
5. Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
6. Spherix Elects New Independent Director, and Elects Chairman of the Board
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
(Date:12/1/2015)... --  MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), a ... an Investigational New Drug Application (IND) with the U.S. ... fully human antibody product HuMab 5B1 as a therapeutic ... the Phase I clinical trial early in 2016. ... planned Phase I trial will evaluate the safety, tolerability ...
(Date:12/1/2015)... 2015  Booth #3506 – Claymount is featuring its full ... of the Radiological Society of North America ... Based in the Netherlands , Claymount is ... (NYSE: VAR ) and is one of the world,s ... state automatic exposure control systems for controlling dose during medical ...
(Date:12/1/2015)... , Dec. 1, 2015  Lexicon Pharmaceuticals, ... that top-line data from its TELECAST Phase ... in treating carcinoid syndrome in cancer patients ... clinical benefit observed in its pivotal TELESTAR ... a companion to TELESTAR primarily to provide ...
Breaking Medicine Technology:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), ... at the Radiological Society of North America (RSNA) 2015 annual meeting through December ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... and SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech ... . Gary has spent a significant amount of time in Sweden since joining ...
Breaking Medicine News(10 mins):